Oxygen Of The Saccharide Radical Bonded Directly To A Cyclohexyl Ring Patents (Class 514/35)
  • Patent number: 10710967
    Abstract: A compound represented by the formula (1), or a salt thereof (X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group, or a heterocyclic group; R3 represents hydrogen atom, or 1 to 3 substituents; R4 and R5 represents hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group, or an alkoxy group), which has an mPGES-1 inhibitory action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of inflammation, pain, rheumatism, and the like.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: July 14, 2020
    Assignee: ASKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto Okada, Youichi Nakano, Takashi Nose, Takahiro Nishimoto, Satoshi Maeda
  • Patent number: 10548912
    Abstract: The present inventors provides one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile-associated disease (CDAD) in a patient according to a dosage regimen comprising: (1) administering to the patient in an initial course of treatment 200 mg of the tiacumicin compound twice a day; (2) monitoring the efficacy of the initial course of treatment in the patient by means of monitoring changes of one or more indicators of CDI or CDAD; (3) assessing whether there is a positive change of the one or the more of the indicators; and (4) switching to an intermittent course of treatment by administering to the patient 200 mg of the tiacumicin compound every other day if the one or the more of the indicators of CDI or CDAD are positively changed.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: February 4, 2020
    Assignee: Astellas Pharma Europe Ltd.
    Inventors: Andreas Johannis Karas, Christopher Mark Longshaw, Leticia Delgado-Herrera, Bernhardt George Zeiher
  • Patent number: 10519181
    Abstract: Compounds, compositions, and methods for treatment and/or prevention of cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood are disclosed. For example, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described and pharmaceutical compositions comprising at least one of the same.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, John M. Peterson
  • Patent number: 10307453
    Abstract: A method for extracting stilbene compounds comprises the following steps: grinding a medicinal material rich in stilbene compounds such as rheum officinale; extracting the medicinal material with a herbal flash extractor for one to four times, 5-20 minutes each time; filtering and combining filtrate and concentrating the filtrate to dryness; the proportion of the medicinal material to a solvent being 1 g: 10 ml-1 g:15 ml.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: June 4, 2019
    Assignee: KPC PHARMACEUTICALS, INC
    Inventors: Yunqi Gong, Jinxin Chen, Fang Fang
  • Patent number: 9981895
    Abstract: Composition, methods of synthesizing trans-arachidin-3; and, methods of use as a dietary supplement, food additive, pharmaceutical, nutraceutical, cosmeceutical, and antioxidant. The methods of production entail organic syntheses using primary alkylamines or primary hydroxyalkyl amines, or carboxy amines (amino acids) with natural carboxylic acids (acetic acid) as catalysts to react isovaleraldehye with trans-resveratrol. The synthesis is carried out in organic solvent, which is composed of an azeotropic mixture comprising toluene with pyridine, n-butanol, n-propanol, 2-propanol, 2-methyl-1-propanol, or other alcohols that form an azeotrope with toluene. The final product is purified and analyzed for the amount of trans-arachidin-3, such as via HPLC, IR, column chromatography, and high-performance counter-current chromatography.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: May 29, 2018
    Assignee: Parnative Inc.
    Inventors: Benjamin Clayton, Jeremy Bandy
  • Patent number: 9937198
    Abstract: A multi-functional composition is disclosed as well as the preparation method and applications thereof. The composition contains a marine algae-derived material and an enzyme inhibitor. The marine algae-derived material is one from the group consisting of natural algal saccharide, alginic acid and alginate or is a mixture of several of them. The enzyme inhibitor is an inhibitor to the enzyme decomposing the material derived from marine algae.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: April 10, 2018
    Assignees: Pinghu Sciscape Bio-Pharmaceutical Technology Co., Ltd., Beijing Bailening Biotechnology Co., Ltd., Suzhou Sciscape Bio-Pharmaceutical Technology Co. Ltd.
    Inventors: Chenggang Zhang, Zhihui Li, Yu Li
  • Patent number: 9925202
    Abstract: Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors. Lymphangioleiomyomatosis (LAM) is a rare lung disease. Some LAM occurances are associated with mutations in the tuberous sclerosis complex (TSC) locus. LAM occurs almost exclusively in women, usually of childbearing age.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: March 27, 2018
    Assignee: BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jane Yu, Chenggang Li
  • Patent number: 9363998
    Abstract: A pesticidal composition comprising a carboxamide compound represented by following formula (I), wherein R1 represents a hydrogen atom or a methyl group, and R2 represents a methyl group, a difluoromethyl group or a trifluoromethyl group, and one or more carbamate compounds selected from group (A) consisting of oxamyl, thiodicarb, carbosulfan, methiocarb and carbofuran is provided by the present invention, and this composition has an excellent pesticidal effect.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: June 14, 2016
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yuichi Matsuzaki
  • Patent number: 9359322
    Abstract: Compounds of the formula: are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: June 7, 2016
    Assignees: Wisconsin Alumni Research Foundation, The Ohio State University Research Foundation
    Inventors: Margaret Clagett-Dame, Robert W. Curley, Jr., Joel R. Walker, Hussein Abou-Issa, Galal A. Alshafie
  • Patent number: 9216185
    Abstract: Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 22, 2015
    Assignee: Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
    Inventors: Alberto Tejedor Jorge, Alberto Lazaro Fernandez, Sonia Camaño Paez, Ana Maria Torres Redondo, José Antonio Lazaro Manero, Manuela Castilla Barba, María del Carmen De Lucas Collantes
  • Patent number: 9175028
    Abstract: Compounds of formula (I?) wherein: R11, R12, R13, R14 and R15 are hydrogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-carbonyloxy, or a G-O— group, and at least one of R11, R12, R13, R14 and R15 is a G-O— group, wherein G is a saccharide residue, X1 is a single bond, or a methylene group, an ethylene group, a trimethylene group, a vinylene group or —CH?CH—CH2—, X2 is —CO—O— or —O—CO—, p and q are integer ofs 0 to 7, and p+q=0 to 8, Y1 is methylene, ethylene or an alkenylene group having a carbon number of 2 to 15 and 1 to 3 double bonds, and R16 and R17 are hydrogen, methyl or ethyl, or R16 and R17 form a C3-6 cycloalkyl group, are useful as GLP-1 secretion promoting agents.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: November 3, 2015
    Assignee: AJINOMOTO CO., INC.
    Inventors: Wataru Kurosawa, Takuya Toyoda, Risa Ubagai, Yoshihito Nogusa, Kana Ohyama, Yusuke Amino
  • Publication number: 20150148308
    Abstract: A harmful arthropod control composition comprising a compound represented by the following Formula (1) wherein each symbol represents definitions described in the specification, and one or more fungicidal compounds, which are selected from among azoles, strobilurins, phenylamides, rice blast controlling compounds, rice sheath blight disease controlling compounds, and other fungicidal compounds. The composition has an excellent controlling effect against harmful arthropods.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 28, 2015
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Tatsuya Suzuki, Atsushi Iwata, Yoshihiko Nokura
  • Publication number: 20150140120
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 21, 2015
    Applicant: ARCHEMIX LLC
    Inventors: Dilara McCauley, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Publication number: 20150141360
    Abstract: A process for preparing a biocidal composition comprising the steps of: (i) dissolving at least one polyol in water to form a water/polyol co-solvent solution; (ii) adding at least one organic acid to the water/polyol co-solvent solution; (iii) adding at least one stabiliser to the water/polyol co-solvent solution; (iv) adding a flavonoid composition comprising at least one flavonoid selected from the group consisting of: poncirin, neoeriocitrin, isonaringin, rhoiflin, naringen, neodiosmin, hesperidin, neohesperidin and naringenin.
    Type: Application
    Filed: July 3, 2013
    Publication date: May 21, 2015
    Inventor: Sean Daly
  • Publication number: 20150110808
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Application
    Filed: December 21, 2012
    Publication date: April 23, 2015
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • Patent number: 9012415
    Abstract: This invention refers to photo-crosslinked hydrogel materials based in gellan gum suitable for tissue engineering and regenerative medicine applications or as drug delivery systems. Formulations of gellan gum with different degrees of acylation serve as precursor material for insertion of a polymerizable moiety. The materials are capable of free radical polymerization with a photo-initiator at mild temperatures and exposure to ultraviolet light, enabling control of reticulation and withstanding the encapsulation of human and animal cells and/or drugs, and any combination thereof. The physicochemical and biological properties can be adjusted by combining different formulations of gellan gum and reaction conditions.
    Type: Grant
    Filed: March 26, 2011
    Date of Patent: April 21, 2015
    Assignee: Stemmatters, Biotecnologia e Medicina Regenerativa S.A.
    Inventors: Joana Catarina Da Silva Correia, Joaquim Miguel Antunes De Oliveira, João Manuel Teixeira De Oliveira, Rui Pedro Amandi Romero De Sousa, Rui Luis Gonçalves Dos Reis
  • Patent number: 9012414
    Abstract: The invention relates to novel eucomic acid (2-(4-hydroxybenzyl)malic acid) derivatives or plant extracts comprising such derivatives, and also to cosmetic or dermatological compositions containing these compounds or these extracts, and to cosmetic care methods using said compositions.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 21, 2015
    Assignees: Guerlain, Universite de Strasbourg, Centre National de la Recherche Scientifique
    Inventors: Charlotte Simmler, Virginie Leplanquais, Emmanuelle Noblesse, Patrice Andre, Annelise Lobstein
  • Publication number: 20150087610
    Abstract: The present invention provides methods and compositions for modifying fertility in a male mammalian subject by contacting the subject's testis cells, germ cells or sperm with a sufficient amount of a composition comprising a ligand that binds, activates, or inhibits activation of, a TAS2R receptor expressed on the cells. Also described are methods for screening a test molecule for its effect on fertility by examining changes in male germ cells, testis cells or sperm resulting from contact with a molecule that binds, activates, or inhibits activation of, a TAS2R receptor expressed on the cells. Compositions for modifying fertility in a mammalian subject, e.g., contraceptive products, include a ligand that binds, inhibits or activates a TAS2R receptor in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 18, 2013
    Publication date: March 26, 2015
    Applicant: Monell Chemcial Senses Center
    Inventors: Liquan Huang, Jiang Xu
  • Publication number: 20150064287
    Abstract: The present invention relates to a method for treating abnormal polyglutamine-mediated diseases comprising: administering a pharmaceutical composition comprising one or more selected from the group consisting of a Gardenia jasminoides extract, geniposide and crocin.
    Type: Application
    Filed: August 19, 2014
    Publication date: March 5, 2015
    Inventors: Guey-Jen LEE-CHEN, Chiung Mei CHEN
  • Publication number: 20150057240
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: February 8, 2013
    Publication date: February 26, 2015
    Inventors: Brian S. J. Blagg, Bhaskar Reddy Kusuma, Teather Sundstrom
  • Patent number: 8962578
    Abstract: The invention relates to novel fungicidally active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide and active compounds listed in the disclosure.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 24, 2015
    Assignee: Bayer CropScience AG
    Inventors: Peter Dahmen, Ulrike Wachendorff-Neumann, Rolf Pontzen, Lutz Assmann, Haruko Sawada
  • Publication number: 20150051164
    Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Inventor: John L. Magnani
  • Publication number: 20150025030
    Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.
    Type: Application
    Filed: June 8, 2013
    Publication date: January 22, 2015
    Applicant: ZHEJIANG YONGNING PHARMACEUTICAL CO LTD
    Inventors: Fengqi Ye, Ben Cai, Min Lu, Yongling Chen
  • Publication number: 20150025028
    Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 22, 2015
    Inventors: Guey-Jen LEE-CHEN, Hsiu-Mei HSIEH, Guan-Chiun LEE
  • Patent number: 8937167
    Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: January 20, 2015
    Assignee: Washington University
    Inventors: James W. Janetka, Zhenfu Han, Scott Hultgren, Jerome S. Pinkner, Corinne Cusumano
  • Publication number: 20150004110
    Abstract: The 1-aryl-2-aryloxyethane compounds of Formula 1 in which n and m are zero or equal to 1, provided that n+m=1, R1 and R2 in particular representing hydrogen atoms, R3 and R4 in particular representing hydrogen atoms, halogen atoms, hydroxy or alkoxy groups, and R5 in particular representing hydrogen atoms, hydroxy, alkyl, alkoxy, amino or nitro groups, in cosmetic compositions intended for anti-ageing and/or depigmenting and/or anti-inflammatory and/or wound-healing care.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 1, 2015
    Applicant: DIVERCHIM
    Inventors: Natacha Frison, Benoit Folleas, Jean-Louis Brayer, Florence Wafflart
  • Patent number: 8921328
    Abstract: Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: December 30, 2014
    Assignee: GlycoMimetics, Inc.
    Inventors: Beat Ernst, Céline E. Weckerle, Jonas K. Egger
  • Publication number: 20140378405
    Abstract: The present invention relates to an extract of Salix spp obtainable by fractioning on a resin and to the process for its preparation. The extract of the invention is characterized by an high content in salicin derivatives, reduced content in high molecular tannins and a content in proanthocyanidins sufficient to inhibit some tissue metal proteases. The product is formulated in oils rich in ?-3 and ?-6 acids which provide a better absorption of the extract active principles, also increasing synergetically their action.
    Type: Application
    Filed: June 24, 2013
    Publication date: December 25, 2014
    Inventors: Ezio BOMBARDELLI, Andrea GIORI, Alessandro ANELLI
  • Publication number: 20140371134
    Abstract: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.
    Type: Application
    Filed: June 18, 2013
    Publication date: December 18, 2014
    Inventor: Jay Richard Ray, II
  • Publication number: 20140357589
    Abstract: The present invention relates to compositions, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a further fungicidally active compound (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Inventors: Thomas SEITZ, Ulrike Wachendorff-Neumann, Peter Dahmen
  • Publication number: 20140323305
    Abstract: The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.
    Type: Application
    Filed: December 6, 2012
    Publication date: October 30, 2014
    Applicant: BASF SE
    Inventors: Joachim Rheinheimer, Violeta Terteryan, Stefan Redlich, Doris Kremzow, Claudia Rosenbaum, Sebastian Georgios Rohrer, Wassilios Grammenos, Christian Pilger, Franz Roehl, Markus Gewehr, Gerd Stammler, Jurith Montag, Hubert Sauter
  • Publication number: 20140315846
    Abstract: An extract of Andrographis paniculata extract containing androgapholide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographolide, neoandrographolide, polysaccharides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Inventors: Jifeng DUAN, Zhiming MA, Xiaoqiang YAN, Weihan ZHANG, Tao WANG, Yu CAI
  • Patent number: 8853175
    Abstract: Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: October 7, 2014
    Assignee: Celgene Corporation
    Inventors: Gondi Kumar, Hon-Wah Man, Roger S. C. Chen, George W. Muller, Anthony J. Frank
  • Publication number: 20140296175
    Abstract: A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and a pharmaceutical acceptable carrier.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 2, 2014
    Applicant: NATIONAL YANG-MING UNIVERSITY
    Inventor: Rong-Tsun Wu
  • Publication number: 20140271474
    Abstract: Radiolabeled tracers for binding to sodium/glucose cotransporters (SGLTs), and their synthesis, are provided. The tracers are high-affinity inhibitors of SGLTs, glycosides labeled with radioactive halogens. Also provided are in vivo and in vitro techniques for using the tracers as analytical tools to study the biodistribution and regulation of SGLTs in health and disease, and to evaluate therapeutic interventions. The ability to monitor radiolabel tracer disposition in real time enables the design of new SGLT inhibitors with lower metabolism and higher efficiency.
    Type: Application
    Filed: June 14, 2012
    Publication date: September 18, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ernest M. Wright, Jorge R. Barrio
  • Publication number: 20140274930
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Evelyne Dietrich, Carl Poisson, Michel Gallant, Stephanie Lessard, Bingcan Liu, Sanjoy Kumar Das, Yeeman Ramtohul, Thumkunta Jagadeeswar Reddy, Julien Martel, Frederic Vallee, Jean-Francois Lévesque
  • Publication number: 20140274931
    Abstract: The present description discloses a novel biologically active ingredient of manuka honey. Specially, the present description discloses a compound represented by the following formula. In this formula, each of R1, R2 and R3 independently represents a hydrogen atom or optionally substituted C1-4 alkyl group, m represents an integer from 1 to 3, each of R4-m, R5-m and R6-m independently represents a hydrogen atom or optionally substituted C1-4 alkyl group, and each of R7, R8, R9 and R10 independently represents a hydrogen atom or optionally substituted C1-4 alkyl group.
    Type: Application
    Filed: October 15, 2012
    Publication date: September 18, 2014
    Inventor: Yoji Kato
  • Publication number: 20140274907
    Abstract: A compound with the formula (I), wherein: R2 is of formula (II), where X is selected from the group comprising: OH, SH, CO2H, COH, N?C?O, NHNH2, CONHNH2, formula (A), formula (B), NHRN, wherein RN is selected from the group comprising H and C1-4 alkyl; RC1, RC2 and RC3 are independently selected from H and unsubstituted C1-2 alkyl; and either: R12 is selected from the group consisting of: (ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; (ib) C1-5 saturated aliphatic alkyl; (ic) C3-6 saturated cycloalkyl; (id) formula (C), wherein each of R21, R22 and R23 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5; (ie) formula (D), wherein one of R25a and R25b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group
    Type: Application
    Filed: October 12, 2012
    Publication date: September 18, 2014
    Applicant: SPIROGEN SARL
    Inventors: Philip Wilson Howard, Arnaud Tiberghien, Scott Jeffrey, Patrick Burke
  • Patent number: 8835448
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., Syndrome X), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type II diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 16, 2014
    Assignee: Melior Pharmaceuticals I, Inc.
    Inventors: Andrew G. Reaume, Michael S. Saporito
  • Patent number: 8828955
    Abstract: The invention aims at finding a highly-safe natural product having glutathione production-enhancing activity, and providing a glutathione production enhancer and a prophylactic/therapeutic agent for diseases caused by glutathione deficiency using that natural product as an active ingredient. The glutathione production enhancer or the prophylactic/therapeutic agent for diseases caused by glutathione deficiency contains, as an active ingredient, a licorice extract composition that contains liquiritin, liquiritigenin, isoliquiritin and isoliquiritigenin but contains substantially no glycyrrhizic acid.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: September 9, 2014
    Assignee: Maruzen Pharmaceuticals Co., Ltd.
    Inventors: Nobuaki Ohto, Toshiyuki Murakami, Hirokazu Ohno
  • Publication number: 20140249099
    Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein.
    Type: Application
    Filed: February 26, 2014
    Publication date: September 4, 2014
    Applicant: TriAct Therapeutics, Inc.
    Inventors: Thomas F. WHITE, Steven SMITH
  • Publication number: 20140249098
    Abstract: The present invention relates to pharmaceutical compositions comprising dapagliflozin and cyclodextrin, preferably (2-hydroxy)propyl-b-cyclodextrin or ?-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin.
    Type: Application
    Filed: June 1, 2012
    Publication date: September 4, 2014
    Applicant: RATIOPHARM GMBH
    Inventors: István Puskas, Lajos Szente
  • Publication number: 20140245496
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Application
    Filed: August 7, 2012
    Publication date: August 28, 2014
    Applicants: EVOLVA SA, INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Joergen Hansen, Esben Halkjaer Hansen, Honey Polur, Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton
  • Publication number: 20140228287
    Abstract: A pharmaceutical composition includes 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof.
    Type: Application
    Filed: April 16, 2014
    Publication date: August 14, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Frerich DE VRIES, Dirk HOERSTERMANN, Ingo LANG, Michael MARK, Randolph SEIDLER, Leo THOMAS
  • Patent number: 8802707
    Abstract: This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis Cancers. These very tiny L-form Cell-Wall-Deficient (CWD) antibiotic-resistant bacteria live within the cytoplasm of cells, including the phagocytic cells (e.g. monocytes, macrophages, lymphocytes, neutrophils and polymorphonuclear cells) of the immune system itself. The cellular proliferation in Cancer is catalysed the action of the same tiny L-form bacteria. They cause the cell nucleus to release mRNA signaling the Th1 cytokine cascade without the need for conventional signaling via, for example, CD4+T -Lymphocytes. Some of these Cytokines and Chemokines, including, without limitation, Cellular Adhesion Molecule (CAM), create the environment which allows the cellular proliferation to start, and then allows the cancerous growth to gain a foothold in the body. Killing these stealthy pathogens removes the environment needed to initiate and feed the cellular proliferation commonly called ‘Cancer’.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: August 12, 2014
    Inventor: Trevor Gordon Marshall
  • Publication number: 20140199235
    Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.
    Type: Application
    Filed: January 31, 2012
    Publication date: July 17, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventors: Jae Min Jeong, Young Kyoung Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee
  • Publication number: 20140200190
    Abstract: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, wherein the galectin is preferably a galectin-3.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Applicant: Galecto Biotech AB
    Inventors: Hakon LEFFLER, Ulf J. NILSSON, Henrik VON WACHENFELDT
  • Publication number: 20140187508
    Abstract: A synergistic fungicidal mixture contains a fungicidally effective amount of a compound of Formula I and at least one fungicide selected from the group consisting of tricyclazole, azoxystrobin, carpropamid, probenazole, kasugamycin, and boscalid.
    Type: Application
    Filed: December 28, 2013
    Publication date: July 3, 2014
    Applicant: Dow AgroScience LLC
    Inventors: DAVID OUIMETTE, RICHARD K. MANN, JOHN TODD MATHIESON, OLAVO CORREA da SILVA
  • Publication number: 20140179625
    Abstract: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.
    Type: Application
    Filed: January 17, 2014
    Publication date: June 26, 2014
    Applicant: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • Publication number: 20140178303
    Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
    Type: Application
    Filed: December 13, 2013
    Publication date: June 26, 2014
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst